News | September 20, 2024
Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL
Stable profits, low leverage to keep credit profiles comfortable
Stable profits, low leverage to keep credit profiles comfortable
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The company is one of the most profitable companies manufacturing speciality chemicals in India
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Since its inception, the company has either acquired or taken a majority stake in five companies
_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
Subscribe To Our Newsletter & Stay Updated
